- Lexicon Pharmaceuticals (LXRX, Financial) to present patient-reported data on diabetic peripheral neuropathic pain (DPNP) at ASPN 2025.
- DPNP affects approximately 9 million patients in the U.S., impacting 30% of type 1 and 50% of type 2 diabetes patients.
- Lexicon is developing pilavapadin, a novel non-opioid treatment for DPNP, with promising early results.
Lexicon Pharmaceuticals, Inc. (LXRX) has announced plans to present important patient-reported data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in Miami Beach, Florida. The presentation, scheduled for July 19, 2025, will focus on the impact of DPNP, a debilitating chronic condition affecting about 9 million individuals in the United States.
Research indicates that DPNP impacts approximately 30% of patients with type 1 diabetes and 50% of those with type 2 diabetes, presenting symptoms such as burning pain and numbness in extremities. This study aims to support the development of pilavapadin, Lexicon's investigational non-opioid treatment for DPNP, meant to alleviate these symptoms.
M. Belinda Hardin, PharmD, BCPS of Lexicon Pharmaceuticals, emphasized that the study aims to amplify the voices of those affected by DPNP globally and to increase healthcare professionals' awareness of the condition's burdens. The presentation titled "Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin" will detail insights from patient experiences to inform clinical practices and development of future treatments.
Pilavapadin, identified through Lexicon's gene science platform, is a selective investigational small molecule targeting AAK1, a novel element in neuropathic pain. It offers a promising non-opioid approach to DPNP by inhibiting neurotransmitter recycling involved in pain signaling. The drug has shown significant results in a Phase 2a study, reducing pain symptoms like burning pain and sleep interference without affecting opiate pathways. Pilavapadin has also been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
